Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 — Providence, Rhode Island

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 is a clinical research site located in Providence, Rhode Island, United States 02903-4923.

Crixeo Clinical Trials Trust Score: 89/100 (GOOD). This profile has not yet been claimed by the site owner.

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 has participated in 1 clinical trials.

Therapeutic areas: Multiple Myeloma (MM), Cancer.

Sponsors: AbbVie.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Providence

Browse all research sites in Rhode Island · View every site in Providence

Sponsor Feasibility Report

Trust Score: 89/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418?

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 has a Crixeo Trust Score of 89/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 conducted?

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 has 1 clinical trials on record. Their work covers Multiple Myeloma (MM), Cancer.

Is Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 accredited by Crixeo Clinical Trials?

Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.